Study in Patients With COPD

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Chronic Disease Chronic Obstructive Pulmonary Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

5 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Site, Phoenix, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of COPD
History of cigarette smoking

Exclusion criteria

Clinical diagnosis of asthma
Significant pulmonary disease other than COPD
Other significant major organ disease(s)

Treatment and study plan

formoterol fumarate

Drug

Primary outcomes

Measure of lung function

Secondary outcomes

Change in lung function, as well as vital signs
Physical Exam results, adverse event reporting, etc

Sponsors and collaborators

Lead sponsor

Dey

Industry

Registry information

Important dates

Primary completion: 2003
Study completion: 2005
First posted: Sep 22, 2005
Registry last updated: Nov 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed